IMRX vs IMUX

Immuneering Corporation vs Immunic, Inc. — Valuation Comparison 2026

IMRX

Biotechnology
Immuneering Corporation
Quality
4.5
out of 10
Value Trap
26
LOW
Price
$5.06
Last close
Models
7/13
Active
VS

IMUX

Biotechnology
Immunic, Inc.
Quality
4.9
out of 10
Value Trap
24
SAFE
Price
$14.97
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType IMRX Fair ValueIMRX Upside IMUX Fair ValueIMUX Upside
Bayesian DCF Intrinsic $1.74 -65.7% $11.51 -23.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.66 -67.2% $6.41 -57.2%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMRX vs IMUX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMRX vs IMUX — Which Stock Is More Undervalued?

IMUX scores higher with a 4.9/10 quality rating vs IMRX's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Immuneering Corporation (IMRX) and Immunic, Inc. (IMUX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMRX currently trades at $5.06 with a QOC of 4.5/10, while IMUX trades at $14.97 with a QOC of 4.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).